65,437 trials
Overweight
Primary: Overweight — 683; 385 participants — p=<0.05
Prostatitis
Primary: Clinical Success — 46; 48; 52 Participants
HIV Infections
Primary: Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin — 1; 2; 6 participants
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. — 56; 76; 94; 0 percentage of subjects — p=<0.001
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Gout
Primary: Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) — 53; 62; 21 Percentage of subjects — p=<0.001
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. — 50; 93; 65; 82 percentage of subjects
Hypertension
Primary: Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 — -0.2; -5.2; -6.4; -8.5 mm Hg
Multiple Myeloma · Stem Cell Transplantation
Primary: Response Rate — 11; 36 Participants
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration — 0.07; 0.05; 0.06 Liter — p=0.871
Migraine Headache
Primary: Pain Relief at 2 Hours After Dose — 99; 258; 239; 64 Participants
Psoriasis
Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16. — 0.78; 0.42 Proportion of participants — p=<0.001
Primary Hypercholesterolemia · Homozygous Familial Hypercholesterolemia
Primary: Safety as Measured by Number of Subjects With at Least One Adverse Event — 45 subjects
Rheumatoid Arthritis
Primary: Number of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24 — 47; 52; 64; 58 Participants — p=0.053
Spondylitis, Ankylosing
Primary: Assessment in Ankylosing Spondylitis 20 Responders at Week 14 — 17; 82; 84; 166 Participants — p=<0.001